BridgeMD
New treatment option for Myeloid Malignancy
Official title Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
ClinicalTrials.gov ID: NCT07263074
What this study is testing
- What it's testing
- This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories [CHORDS]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older
You may be able to join if
- Patients
- Age \>21 years old
- Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN)
- Being considered for alloHCT
- Able to provide informed consent
You likely can't join if
- Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures...
- Age \>18 years old
- Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in...
- Caregiver may be paid/professional or informal caregiver
- Able to provide informed consent
- Able to speak English Exclusion Criteria: 1) None Hematologists Inclusion criteria: 1) Hematologists of the patients who agree to enroll on the study...
See the full eligibility criteria
- Patients
- Age \>21 years old
- Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN)
- Being considered for alloHCT
- Able to provide informed consent
- Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated.
- Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria:
- Age \>18 years old
- Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters."
- Caregiver may be paid/professional or informal caregiver
- Able to provide informed consent
- Able to speak English Exclusion Criteria: 1) None Hematologists Inclusion criteria: 1) Hematologists of the patients who agree to enroll on the study who are part of WCI. Exclusion criteria 1) None
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, New York, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.